102 related articles for article (PubMed ID: 11487034)
1. Anti-GPIIb/IIIa drugs: current strategies and future directions.
Coller BS
Thromb Haemost; 2001 Jul; 86(1):427-43. PubMed ID: 11487034
[TBL] [Abstract][Full Text] [Related]
2. Platelet glycoprotein IIb/IIIa inhibitors.
Rosove MH
Best Pract Res Clin Haematol; 2004 Mar; 17(1):65-76. PubMed ID: 15171958
[TBL] [Abstract][Full Text] [Related]
3. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
[TBL] [Abstract][Full Text] [Related]
4. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
6. Platelet glycoprotein IIb/IIIa inhibition and its clinical use.
Huang F; Hong E
Curr Med Chem Cardiovasc Hematol Agents; 2004 Jul; 2(3):187-96. PubMed ID: 15320785
[TBL] [Abstract][Full Text] [Related]
7. Use of GPIIb/IIIa inhibitors in cardiovascular medicine.
Ahrens I; Peter K; Bode C
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):233-42. PubMed ID: 15030283
[TBL] [Abstract][Full Text] [Related]
8. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
Kandzari DE
Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
[TBL] [Abstract][Full Text] [Related]
9. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
Harrington RA
Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
[TBL] [Abstract][Full Text] [Related]
10. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
11. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Quinn MJ; Moliterno DJ
Minerva Cardioangiol; 2002 Oct; 50(5):547-53. PubMed ID: 12384636
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging.
Sebastian M; Makkar R
Drugs Aging; 1999 Sep; 15(3):207-18. PubMed ID: 10503813
[TBL] [Abstract][Full Text] [Related]
13. Oral glycoprotein IIb/IIa antagonists for unstable angina--is there still a chance for the oral substances?
Darius H
Thromb Res; 2001 Sep; 103 Suppl 1():S117-24. PubMed ID: 11567679
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding?
Doggrell SA
Drugs Today (Barc); 2001 Aug; 37(8):509-531. PubMed ID: 12743636
[TBL] [Abstract][Full Text] [Related]
15. Targeting the platelet integrin GPIIb/IIIa.
Hagemeyer CE; Peter K
Curr Pharm Des; 2010; 16(37):4119-33. PubMed ID: 21247395
[TBL] [Abstract][Full Text] [Related]
16. Progress in the field of GPIIb/IIIa antagonists.
Hanson J; de Leval X; David JL; Supuran C; Pirotte B; Dogné JM
Curr Med Chem Cardiovasc Hematol Agents; 2004 Apr; 2(2):157-67. PubMed ID: 15320798
[TBL] [Abstract][Full Text] [Related]
17. New adjunctive therapy for ischemic syndromes.
De Jong MJ; Wright SL
Crit Care Nurs Clin North Am; 1999 Sep; 11(3):355-71. PubMed ID: 10786482
[TBL] [Abstract][Full Text] [Related]
18. Intravenous glycoprotein IIb/IIIa antagonists: their benefits, problems and future developments.
Curtin R
Curr Pharm Des; 2004; 10(14):1577-85. PubMed ID: 15134556
[TBL] [Abstract][Full Text] [Related]
19. GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiology.
Kleiman NS
Drugs R D; 1999 May; 1(5):361-70. PubMed ID: 10566065
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Implications of a Specific Murine Monoclonal Antibody (7E3) to the Platelet Receptor GPIIb/IIIa.
Bhattacharya S; Machin SJ; Lahiri A
Platelets; 1992; 3(3):119-24. PubMed ID: 21043903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
